Have a feature idea you'd love to see implemented?
Let us know!
PSTX Poseida Therapeutics Inc
Price (delayed)
$2.71
Market cap
$264.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.62
Enterprise value
$297.52M
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida
Highlights
The gross profit has soared by 71% from the previous quarter
The revenue has soared by 71% from the previous quarter
Poseida Therapeutics's equity has increased by 43% QoQ but it has decreased by 29% YoY
The quick ratio has grown by 29% since the previous quarter but it has declined by 2.5% year-on-year
Key stats
What are the main financial stats of PSTX
Market
Valuations
Earnings
Shares outstanding
97.47M
Market cap
$264.13M
Enterprise value
$297.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.02
Price to sales (P/S)
1.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.97
Revenue
$150.86M
EBIT
-$51.64M
EBITDA
-$46.16M
Free cash flow
-$17.13M
Per share
Balance sheet
Liquidity
EPS
-$0.62
Free cash flow per share
-$0.18
Book value per share
$0.9
Revenue per share
$1.55
TBVPS
$2.96
Total assets
$293.58M
Total liabilities
$206.37M
Debt
$82.73M
Equity
$87.21M
Working capital
$172.44M
Debt to equity
0.95
Current ratio
3.2
Quick ratio
3.14
Net debt/EBITDA
-0.72
Margins
Efficiency
Dividend
EBITDA margin
-30.6%
Gross margin
100%
Net margin
-40.3%
Operating margin
-41.4%
Return on assets
-21.5%
Return on equity
-72.3%
Return on invested capital
-22.2%
Return on capital employed
-24%
Return on sales
-34.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PSTX stock price
How has the Poseida Therapeutics stock price performed over time
Intraday
-0.37%
1 week
-15.58%
1 month
8.4%
1 year
3.83%
YTD
-19.35%
QTD
-5.24%
Financial performance
How have Poseida Therapeutics's revenue and profit performed over time
Revenue
$150.86M
Gross profit
$150.86M
Operating income
-$62.5M
Net income
-$60.76M
Gross margin
100%
Net margin
-40.3%
Poseida Therapeutics's net margin has surged by 85% YoY and by 68% QoQ
The operating margin has surged by 85% year-on-year and by 69% since the previous quarter
The gross profit has soared by 71% from the previous quarter
The revenue has soared by 71% from the previous quarter
Growth
What is Poseida Therapeutics's growth rate over time
Valuation
What is Poseida Therapeutics stock price valuation
P/E
N/A
P/B
3.02
P/S
1.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.97
PSTX's EPS has soared by 60% YoY and by 47% QoQ
Poseida Therapeutics's equity has increased by 43% QoQ but it has decreased by 29% YoY
The P/B is 16% more than the 5-year quarterly average of 2.6 but 16% less than the last 4 quarters average of 3.6
The revenue has soared by 71% from the previous quarter
The stock's price to sales (P/S) is 49% less than its last 4 quarters average of 3.4
Efficiency
How efficient is Poseida Therapeutics business performance
PSTX's ROS has soared by 86% YoY and by 71% QoQ
PSTX's ROA is up by 49% year-on-year and by 46% since the previous quarter
The ROIC is up by 48% QoQ and by 48% YoY
PSTX's ROE is up by 40% since the previous quarter and by 17% year-on-year
Dividends
What is PSTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PSTX.
Financial health
How did Poseida Therapeutics financials performed over time
The total assets is 42% more than the total liabilities
The current ratio has grown by 29% from the previous quarter but it has contracted by 2.4% YoY
The quick ratio has grown by 29% since the previous quarter but it has declined by 2.5% year-on-year
Poseida Therapeutics's debt is 5% lower than its equity
Poseida Therapeutics's equity has increased by 43% QoQ but it has decreased by 29% YoY
Poseida Therapeutics's debt to equity has increased by 36% YoY but it has decreased by 31% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.